Mutational analysis of CYP1B1 gene in Iranian pedigrees with glaucoma reveals known and novel mutations

Author(s):  
Babak Emamalizadeh ◽  
Yousef Daneshmandpour ◽  
Somayeh Kazeminasb ◽  
Ehsan Aghaei Moghadam ◽  
Zahra Bahmanpour ◽  
...  
2008 ◽  
Vol 53 (8) ◽  
pp. 681-687 ◽  
Author(s):  
Tawhida Y. Abdelghaffar ◽  
Solaf M. Elsayed ◽  
Ezzat Elsobky ◽  
Bettina Bochow ◽  
Janine Büttner ◽  
...  

2005 ◽  
Vol 90 (8) ◽  
pp. 4762-4770 ◽  
Author(s):  
James P. G. Turton ◽  
Rachel Reynaud ◽  
Ameeta Mehta ◽  
John Torpiano ◽  
Alexandru Saveanu ◽  
...  

Context: Mutations within the gene encoding the pituitary-specific transcription factor POU1F1 are associated with combined pituitary hormone deficiency (CPHD). Most of the affected individuals manifest GH, prolactin, and TSH deficiency. Objective: We have now screened 129 individuals with CPHD and isolated GH deficiency for mutations within POU1F1. Results: Causative mutations were identified in 10 of 129 individuals (7.8%). Of these, five patients harbored the dominant negative R271W mutation, which is a well-recognized mutational hot spot. We have also identified a second frequently occurring mutation, E230K, which appears to be common in Maltese patients. Additionally, we describe two novel mutations within POU1F1, an insertion of a single base pair (ins778A) and a missense mutation (R172Q). Functional studies have revealed that POU1F1 (E230K) is associated with a reduction in transactivation, although DNA-binding affinity is similar to the wild-type protein. On the other hand, POU1F1 (R172Q) is associated with a reduction in DNA binding and transactivation, whereas POU1F1 (ins778A) is associated with loss of DNA binding and a reduction in transactivation. Conclusions: Our data suggest that the phenotype associated with POU1F1 mutations may be more variable, with the occasional preservation of TSH secretion. Additionally, our data revealed POU1F1 mutations in three patients who were diagnosed as having ACTH deficiency but who, on further evaluation, were found to have normal cortisol secretion. Hence, elucidation of the genotype led to further evaluation of the phenotype, with the cessation of cortisol replacement that had been commenced unnecessarily. These data reflect the importance of mutational analysis in patients with CPHD.


1999 ◽  
Vol 7 (3) ◽  
pp. 274-286 ◽  
Author(s):  
Karen Grønskov ◽  
Thomas Rosenberg ◽  
Annie Sand ◽  
Karen Brøndum-Nielsen

2009 ◽  
Vol 13 (6) ◽  
pp. 761-764 ◽  
Author(s):  
Khalda Amr ◽  
Ahmed Katoury ◽  
Mohamed Abdel-Hamid ◽  
Randa Bassiouni ◽  
Mona Ibrahim ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10516-10516 ◽  
Author(s):  
Xunhai Xu ◽  
Yufeng Shen ◽  
William Dewitt ◽  
Deep Pandya ◽  
Farideh Z. Bischoff ◽  
...  

10516 Background: The molecular signature of circulating tumor cells (CTCs) may serve as a surrogate marker for accurate description of the metastatic tumor of interest, especially in the setting of treatment response and selection. We present a method for mutational analysis of CTCs in metastatic breast cancer (MBC) patients by using an emulsion-formulated, semiconductor-based, targeted clonal sequencing platform. Methods: CTCs in MBC patients were enriched by a microfluidic OncoCEE device using antibodies against both epithelial and mesenchymal markers. Genomic DNA was extracted from enriched CTC samples. Emulsion-based multiplex-PCR targeted for various cancer genes was performed, after which semiconductor-based deep sequencing was completed. The read error rates were analyzed based on quality score and context of sequence including homopolymers. Statistical significance for each mutational analysis was assessed using a method based on beta-binomial distribution. Results: Of the 17 patients samples obtained, we were able to enrich CTC samples in 9 of them (CTC range 1-1063, median=12). Multiplex targeted sequencing was performed on DNA from the enriched CTC patient samples (purity range 0.3-6%). Greater than 3000-fold coverage was accomplished. Missense mutations at E545D on PIK3CA (p= 2.0e-07), F354L on STK11 (p=2.0e-04), and Q61R on NRAS (p=2.0e-07) were detected. Novel mutations of L540F and Q1033K within the hot spot regions of PIK3CA were observed (p=1.3e-04). Genomic DNA from WBCs from a healthy female was analyzed concurrently as a negative control, in which none of the mutations were observed. Conclusions: Mutational analysis of CTCs in MBC patients can be accomplished by deep sequencing. We developed a de novo protocol for clonal mutation analysis on CTCs in MBC and detected various significant and novel mutations. We anticipate reporting sequencing results on CTCs and matched WBCs, as negative controls, from 40 MBC patients. This will provide the foundation for the future studies in which we will compare the mutational profile between CTCs and primary/metastatic tumors. We intend to validate clonal mutational analysis of CTCs as a predictive blood-based biomarker in subsequent trials.


2007 ◽  
Vol 53 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Chloe Miu Mak ◽  
Ching-Wan Lam ◽  
Sidney Tam ◽  
Ching-Lung Lai ◽  
Lik-Yuen Chan ◽  
...  

Author(s):  
Kleopatra H. Schulpis ◽  
Georgia Thodi ◽  
Konstantinos Iakovou ◽  
Maria Chatzidaki ◽  
Yannis Dotsikas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document